phosphotyrosine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbhuiya, MA; Chaerkady, R; Chen, L; Fackler, MJ; Gabrielson, E; Gill, PS; Jelinek, C; Kashyap, MK; Kim, MS; Leal-Rojas, P; Ling, M; Liu, R; Ma, B; Marimuthu, A; Merino, V; Pandey, A; Renuse, S; Roa, JC; Sahasrabuddhe, NA; Stearns, V; Sukumar, S; Wu, X; Yang, Y; Zahari, MS; Zahnow, CA; Zhang, Z; Zhong, J | 1 |
1 other study(ies) available for phosphotyrosine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
Topics: Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme Activation; Female; Fourier Analysis; Humans; Kaplan-Meier Estimate; Mass Spectrometry; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Phenotype; Phosphorylation; Phosphotyrosine; Protein Interaction Maps; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA Interference; Signal Transduction; Time Factors; Transfection; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |